The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Says it all
"With our this simple, 5-minute, painless intervention our Steriwave treatment makes a life-saving impact - in this case, 468 spine surgery patients saved from potentially lethal infections - more than enough to fill a 747 plane. We are truly grateful to Professor Street and the research staff at VGH for their pursuit of better patient outcomes. Postoperative spine infection can be a devastating and expensive complication after spine surgery, with patients at high risk for chronic pain, paralysis, return to the operating room, poor long-term outcomes, and even death. This study conclusively demonstrates that Steriwave is setting a new standard for safety and performance in infection control."
**END**
9.6-9.975
very small margin
Expecting a JUMP
when next good news
arrives
dyor - imho
Hasbeen
Has been short listed
This is good news
International recognition
is very important
Read the half year report
It looks good in my opinion
Bodes well for getting to breakeven
in 2024 with all great news of more
hospitals coming on line and brand
recognition gaining momentum
surpassing all expectations
imho - dyor
Just bought more @ 9.67p
Am expecting a JUMP
imho - dyor
All indications are that this is a multi-bagger investment opportunity currently below 10p
RBC target is 60p and personally I have no doubt SP will exceed that
imho - dyor
Photodisinfection uses a photosensitizer and a specific wavelength of light to trigger photochemical reactions that produce reactive oxygen species. These reactive oxygen species are lethal to a broad spectrum of microbes, including bacteria, fungi, and viruses. Importantly, photodisinfection does not induce antimicrobial resistance formation.
Photodisinfection is an easy-to-use alternative to topical antibiotics and antifungals because it is highly effective against all types of disease-causing pathogens, including MDR and XDR strains.
Ondine has pioneered nasal photodisinfection as a rapid, non-antibiotic method for decolonizing the nose of the pathogens carried by patients that can lead to HAIs. Steriwave uses a proprietary red light-activated agent to eliminate infection-causing bacteria, viruses, and fungi in the nose, a major reservoir of germs[2], without causing resistance. At the Mazankowski Alberta Heart Institute, Steriwave replaced the previous standard of care, the antibiotic mupirocin. Mupirocin is commonly used for nasal decolonization to prevent SSIs, but has poor rates of patient compliance and reported resistance rates as high as 81%.[3]
10.025-10.34p
good time to buy in my opinion
(before more great news makes SP rise)
dyor
10.575-11.195p
my purchase earlier is shown as sell
It is a good time to buy more (before sky-rocket)
imho - dyor
Nova Scotia's largest hospital is the latest to implement Steriwave nasal photodisinfection for use prior to orthopedic surgery Canadian life sciences company Ondine Biomedical's (LON: OBI) Steriwave® nasal photodisinfection for the prevention of healthcare-associated infections (HAIs) is now available in hospitals across Canada. The latest hospital to implement Steriwave for its orthopedic surgery patients is the Queen Elizabeth II Health Sciences Centre in Halifax, affiliated with Dalhousie University and the largest hospital in Nova Scotia, located on Canada's East Coast.
Steriwave is a highly effective method of preventing infections following surgery. This is particularly important due to growing concern about antimicrobial resistance (AMR), as hospitals must adapt their protocols to combat the rapid rise of drug-resistant pathogens
BRIEF: For the six months ended 30 June 2023, Ondine Biomedical Inc revenues increased 63% to C$428K. Net loss decreased 8% to C$7.9M. Revenues reflect Canada segment increase of 49% to C$390K, United States segment increase from C$0K to C$38K. Lower net loss reflects Research and development decrease of 17% to C$2.2M (expense), General and administration decrease of 7% to C$4.7M (expense).
Fundraising
We are confident in our plans to raise capital to fund the key Phase 3 clinical trial, our ongoing commercial expansion plans, and to fund the Company's operating expenses more generally as we seek to attain short-term milestone objectives and prepare to scale further.
The rise of antimicrobial resistance ("AMR") is driving governments and research institutes to seek new solutions to combat antimicrobial-resistant pathogens and help prevent millions of deaths. Because of the demonstration of efficacy against ESKAPE and extremely drug-resistant pathogens of major concern to global health authorities, we are accelerating our pursuit of non-dilutive funding opportunities and numerous AMR-related government initiatives
RBC target of 60p looks quite achievable in 2024
as the good news continues to accumulate
and as I continue to gradually add to my holding
Expect 25p+ by year-end
is my wild estimate
dyor imho
Alberta Health Services has expanded its use of Steriwave nasal #photodisinfection to reduce the incidence of surgical site infections (SSIs) in orthopedic surgery following a successful pilot at the Mazankowski Alberta Heart Institute #infectioncontrol
This baby is going to brilliant i m h o
Expect 20p very soon
inho - dyor
Up 23% and this is only the beginning
Target 60p